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Amiodarone, a class III antiarrhytmic agent, is a benzo-
furan derivative containing 75 mg iodide per 200 mg
tablet. During the metabolism of 200 mg of the drug
approximately 6-8 mg of inorganic iodine is released into
the systemic circulation. Amiodarone is very lipophilic and
concentrates in various tissues and organs such as adipose
tissue, skeletal muscles, myocardium, liver, lung and thyr-
oid. Amiodarone is dealkylated in the liver to its major
active metabolite desethylamiodarone. Amiodarone ther-
apy is associated with a number of side effects, including
thyroid dysfunction – thyrotoxicosis in 2-15% and
hypothyroidism in 5-20% of patients, respectively. The
effects of amiodarone on thyroid function depend on
underlying thyroid status and dietary iodine intake.
Patients with autoimmune thyroid disease are more likely
to develop hypothyroidism due to failure to escape from
Wolff-Chaikoff effect. In patients with multinodular goiter
or latent Graves’ disease hyperthyroidism may occur.
Amiodarone may also cause destructive thyroiditis in
patients without underlying thyroid disease. Thyrotoxico-
sis may be a result of increased synthesis of thyroid hor-
mones (type 1) or of their excessive release due to a direct
damage of thyroid cells caused by amiodarone, its metabo-
lite desethylamiodarone or iodine (type 2). The distinction
between type 1 and type 2 thyrotoxicosis is crucial, since
therapy is different in these two types. The differential
diagnosis is based on the presence of goiter, evaluation of
thyroid autoantibodies, colour flow Doppler image, thyroid
uptake and on the response to steroids or perchlorate.
Patients with type 1 thyrotoxicosis require thionamides
or potassium/sodium perchlorate, while those with type
2 – corticosteroids. Hypothyroidism is treated with L-thyr-
oxine. The signs and symptoms of amiodarone-induced
thyrotoxicosis and hypothyroidism can be scanty. There-
fore, all patients treated with amiodarone need periodic
examination of thyroid function. Apart from inducing thyr-
oid dysfunction, amiodarone causes hypercholesterolemia
due to decreased expression of the LDL receptor gene,
which is regulated by T3. Adverse effects of amiodarone
have led to the search for analogues with the same efficacy
but safer profile. Dronedarone is structurally related to
amiodarone but does not contain iodine atoms and does
not increase the incidence of thyroid disease. Dronedarone
appears to be less-effective but may be beneficial for
patients with atrial fibrillation or flutter who are at risk of
developing amiodarone induced thyroid dysfunction.
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